<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770246</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-117-201</org_study_id>
    <secondary_id>2020-004770-22</secondary_id>
    <nct_id>NCT04770246</nct_id>
  </id_info>
  <brief_title>TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations</brief_title>
  <official_title>A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic&#xD;
      solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study TAS-117-201 is an open-label, single-arm Phase 2 study evaluating the efficacy, safety,&#xD;
      tolerability, pharmacokinetics, and pharmacodynamics of TAS-117 in patients with advanced or&#xD;
      metastatic solid tumors harboring germline PTEN inactivating mutations. The study will be&#xD;
      conducted in two parts:&#xD;
&#xD;
        -  Part A: Safety lead-in (Dose Escalation and Dose Regimen Confirmation)&#xD;
&#xD;
        -  Part B: Single-arm Phase 2 study&#xD;
&#xD;
      Patients will receive TAS-117 orally every day or intermittently on a 21-day cycle&#xD;
&#xD;
        -  Part A (Dose Escalation): up to 36 adult patients with advanced or metastatic solid&#xD;
           tumors (excluding primary brain tumors) irrespective of gene alterations. The Dose&#xD;
           Escalation consists of 2 cohorts: Daily Dose Regimen and Intermittent Dose Regimen.&#xD;
&#xD;
        -  Part A (Dose Regimen Confirmation): approximately 6 adult or adolescent patients with&#xD;
           advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline&#xD;
           PTEN inactivating mutations&#xD;
&#xD;
        -  Part B (Phase 2): approximately 54 adult or adolescent patients with advanced or&#xD;
           metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN&#xD;
           inactivating mutations&#xD;
&#xD;
      Treatment will continue until disease progression, unacceptable toxicity, or any other of the&#xD;
      criteria for treatment discontinuation is met. For patients who discontinue treatment for&#xD;
      reasons other than disease progression, tumor assessments should be continued until&#xD;
      radiologic disease progression is documented or until initiation of subsequent new anticancer&#xD;
      therapy (whichever occurs first).&#xD;
&#xD;
      Patients will be followed for survival every 12 weeks (Â±2 weeks) until survival events&#xD;
      (deaths) have been reported for 75% of enrolled patients or the study is terminated early by&#xD;
      the Sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events and dose-limiting toxicities (safety and tolerability) and MTD of TAS-117 in Part A</measure>
    <time_frame>21 days for DLT evaluation, approximately 7 months for the others</time_frame>
    <description>Number of patients with abnormal laboratory values, treatment emergent AEs, abnormal vital signs and ECG, and Dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) of TAS-117 in Part A</measure>
    <time_frame>21 days for DLT evaluation, approximately 7 months for the others</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) in Part B (including all patients with germline PTEN mutations in Part A)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>ORR, defined as the proportion of patients experiencing a best overall response of CR or PR per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety) in Part B</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Number of patients with abnormal laboratory values, treatment-emergent AEs, abnormal vital signs and ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>DCR, defined as the proportion of patients experiencing a best overall response of stable response (SD), PR, or complete response (CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>DOR, defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>PFS, defined as the time from date of the first dose of study treatment to the date of disease progression based on Investigator assessment of radiographic images or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>OS, defined as the time from the date of first dose to the death date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) profile of TAS-117 in Part A</measure>
    <time_frame>21 days</time_frame>
    <description>area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) profile of TAS-117 in Part A</measure>
    <time_frame>21 days</time_frame>
    <description>time to reach maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) profile of TAS-117 in Part A</measure>
    <time_frame>21 days</time_frame>
    <description>terminal elimination half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) profile of TAS-117 in Part A</measure>
    <time_frame>21 days</time_frame>
    <description>maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) profile of TAS-117 in Part A</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluate Total and Phosphorylated AKT and PRAS40</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations</condition>
  <condition>Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations</condition>
  <arm_group>
    <arm_group_label>TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid tumors irrespective of gene alterations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid tumors irrespective of gene alterations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid tumors with germline PTEN inactivating mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-117 Phase 2 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid tumors with germline PTEN inactivating mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-117</intervention_name>
    <description>TAS-117 will be dosed orally every day on a 21-day cycle</description>
    <arm_group_label>TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-117</intervention_name>
    <description>TAS-117 will be dosed intermittently on a 21-day cycle</description>
    <arm_group_label>TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-117</intervention_name>
    <description>TAS-117 will be dosed orally every day or intermittently on a 21-day cycle</description>
    <arm_group_label>TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-117</intervention_name>
    <description>TAS-117 will be dosed orally every day or intermittently on a 21-day cycle</description>
    <arm_group_label>TAS-117 Phase 2 (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          2. Dose Escalation in Part A&#xD;
&#xD;
               1. â¥18 years of age.&#xD;
&#xD;
               2. Histologically or cytologically confirmed advanced or metastatic solid tumors&#xD;
&#xD;
               3. Has progressed after standard treatment for advanced or metastatic disease or was&#xD;
                  intolerant to or ineligible for available standard therapies.&#xD;
&#xD;
               4. Patients with solid tumors irrespective of gene alterations.&#xD;
&#xD;
               5. Patients with at least one measurable or non-measurable lesion per RECIST1.1&#xD;
&#xD;
          3. Dose and Regimen Confirmation in Part A and Phase 2 (Part B)&#xD;
&#xD;
               1. â¥12 years of age. Patients age â¥12 and &lt;18 years must have a body weight of â¥40&#xD;
                  kg.&#xD;
&#xD;
               2. Histologically confirmed advanced or metastatic solid tumors.&#xD;
&#xD;
               3. Has progressed after standard treatment for advanced or metastatic disease or was&#xD;
                  intolerant or ineligible to available standard therapies.&#xD;
&#xD;
               4. Patients with locally confirmed germline PTEN inactivating mutations determined&#xD;
                  from a blood sample.&#xD;
&#xD;
               5. Patients with at least one measurable lesion per RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. History or current evidence of interstitial lung disease that requires steroid&#xD;
             medication.&#xD;
&#xD;
          2. Current evidence of diabetes mellitus that requires insulin therapy.&#xD;
&#xD;
          3. Prior treatment with PI3K/AKT/mTOR pathway inhibitors.&#xD;
&#xD;
          4. Patients with primary brain tumor.&#xD;
&#xD;
          5. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord&#xD;
             compression, or symptomatic or unstable brain metastasis.&#xD;
&#xD;
          6. Currently receiving chronic corticosteroid therapy of â¥10 mg/day of prednisone or its&#xD;
             equivalent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Osamu Takahashi, MD, PhD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lerner Research Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Franois Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>Cote-D'or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile De France</state>
        <zip>98405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAS-117</keyword>
  <keyword>AKT inhibitor</keyword>
  <keyword>Allosteric inhibitor</keyword>
  <keyword>Advanced solid tumor</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>PTEN</keyword>
  <keyword>Germline PTEN</keyword>
  <keyword>Inactivating mutation</keyword>
  <keyword>Adolescent patients</keyword>
  <keyword>Adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

